Suzhou Zelgen Biopharmaceuticals (SHA:688266) will conduct clinical trials into ZG005 for injection in combination with other therapies after receiving the approval of the Chinese drug administration, according to a Shanghai Stock Exchange filing on Tuesday.
The drug will be tested with a platinum-containing chemotherapy regimen to treat patients with advanced biliary tract cancer, the biopharmaceutical company said.
The company's shares rose more than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments